- Targeting Sugar Molecules in Sugar-Immune Therapy
- Monkeypox Initial Infection Provides Protection Against Secondary Infection
- What is Genetic Toxicity of Base Editing and Prime Editing?
- What is the Scientific Foundation of mRNA Technology?
- This amino acid can significantly alleviate post-COVID-19 sequelae!
- What are Challenges in CAR-T Cell Therapy for Cancer treatment?
- Cardiovascular Diseases Linked to COVID-19 Infections
- FDA’s First Potential TIL Therapy Review Delayed: How to Understand FDA’s “Resource Constraints”?
- A Chinese Doctor Accused of Accepting Bribes Totaling US$166 Million
- Nuclear contaminated water: Japanese government paid bribes and corrected the IAEA report
- Top 20 Companies of Instruments and Medical Equipment In The World
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- How long can the patient live after heart stent surgery?
Vaccine giant starts patent war: GSK sues Pfizer for RSV vaccine patent infringement.
British vaccine manufacturer GlaxoSmithKline (GSK) formally sued Pfizer for patent infringement of respiratory syncytial virus (RSV) vaccine in a US court on August 2.
In the complaint, GSK alleges that Pfizer’s RSV vaccine infringes four of GSK’s patents related to antigens used in its vaccine.
In May of this year, both GSK and Pfizer’s RSV vaccines have been approved by the FDA for adults aged 60 and over. Some vaccines are already available for sale to the public through retail pharmacies.
However, the lawsuit does not involve RSV vaccine products used in infants.
The lawsuit pointed out that Pfizer started researching the RSV vaccine project in 2013, at least seven years later than the GSK vaccine project, and that Pfizer had known GSK’s patented technology since at least October 2019, when Pfizer began to question the European version patent of GSK vaccine. effectiveness.
According to public information, GSK will seek monetary damages, including lost profits and royalties due to Pfizer’s alleged patent infringement. GSK also asked a judge to block Pfizer from making and selling its RSV vaccine product in the United States for adults 60 and older.
In response to the latest lawsuit, GSK wrote in a statement in response to Yicai Global: “GSK is engaged in active legal proceedings with Pfizer in multiple jurisdictions on multiple patents related to RSV vaccines. These actions will not impact on GSK’s ability to launch an RSV vaccine.”
Due to ongoing litigation, GSK said it could not comment further at this time.
In response to GSK’s lawsuit, a Pfizer spokesman said it has full confidence in its intellectual property rights and will firmly defend its right to bring innovative RSV vaccines to patients.
This is not GSK’s first legal battle with Pfizer over patent rights. In 2016, GSK sued Pfizer in an Irish court, accusing it of infringing on GSK’s meningitis vaccine patent.
In recent years, with the rapid development of new vaccine technologies, related patent infringement prosecutions have become more frequent.
In August last year, the American vaccine manufacturer Moderna sued Pfizer and its German partner BioNTech for infringing the patent rights of its COVID-19 vaccine. Pfizer and BioNTech filed a countersuit last December.
GSK sues Pfizer for RSV vaccine patent infringement
(source:internet, reference only)